

September 24, 2008

APA DSM-V Work Group Member

Name, Degree: Murray B. Stein, M.D., M.P.H., FRCPC

Role(s) in Work Group: Member, Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group

Institutional Affiliation(s): UCSD & VA San Diego Health Care System

City, State: San Diego, CA

Biographical Sketch:

Murray B Stein MD, MPH, FRCPC is Professor of Psychiatry and Family & Preventive Medicine at the University of California San Diego (UCSD), where he directs the Anxiety & Traumatic Stress Disorders Program. He is also a clinician-scientist at the VA San Diego Healthcare System. Dr. Stein's research interests include the epidemiology, neurobiology, and treatment of anxiety disorders especially social phobia, panic disorder, and posttraumatic stress disorder. He has written or co-written over 300 peer-reviewed scientific articles on these topics, including publications in journals such as *The Lancet*, *Journal of the American Medical Association*, *American Journal of Psychiatry*, and *Archives of General Psychiatry*.

His federally funded research includes studies of interventions for anxiety disorders in primary care, pharmacological approaches to treatment-resistant anxiety disorders, and functional neuroimaging research in anxiety and trauma-related disorders. Dr. Stein is Principal Investigator of the Department of Defense-funded Posttraumatic Stress Disorder/Traumatic Brain Injury Clinical Consortium (2008-2013). He is a member of the Board of Directors and the Scientific Advisory Board of the Anxiety Disorders Association of America (ADAA), a Fellow of the American College of Neuropsychopharmacology (ACNP), and Deputy Editor for the journal *Depression & Anxiety*. Dr. Stein chaired the American Psychiatric Association Workgroup to Revise the Panic Disorder Treatment Guidelines (2006-2008). He is currently Scientific Chair of the NIMH Interventions in Mood and Anxiety (ITMA) Review Group (2006-2009).

Dr. Stein graduated from the University of Manitoba and completed his residency and post-residency fellowship at the University of Toronto and at the National Institute of Mental Health in Bethesda, Maryland, USA. He later completed a Master of Public Health degree at the Johns Hopkins University Bloomberg School of Public Health.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
	2005-2008	Scientific Advisory Board
Anxiety Disorders Association of America	2007-2008	Board of Directors
Society of Biological Psychiatry	2005-2008	Member

International Society of Traumatic Stress Studies	2005-2008	Member
---	-----------	--------

The two tables below represent Dr. Stein's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of year.

Dr. Stein has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

KEY NUMBER: 1. Consultation Fees (include scientific advisory boards) 2. Full- or Part-time Employee 3. Industry-related Grant-Research Support received or pending 4. Honoraria (includes Speakers' Bureau) 5. Stock or other financial options	6. Expert testimony 7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product) 8. Patents received or pending 9. Officer, director/trustee, executive (specify) 10. Other (specify)
--	---

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
Forest	2005	1
	2006	1
	2007	1
GlaxoSmithKline	2005	1
	2006	1
AstraZeneca	2005	1
Eli Lilly	2006	1, 3
	2007	3
Hoffmann – La Roche	2005	3
	2006	3
	2007	3
Jazz Pharma	2005	1
	2006	1
	2007	1
Bristol Myers-Squibb	2007	1
Johnson & Johnson	2005	1
	2006	1

UPDATED 9.22.08

Braincells, Inc.	2007	1
Avera Pharma	2005 2006	1 1
Depression & Anxiety (journal)	2005 2006 2007	10 (Deputy Editor)

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
Forest Pharma	2008	1
Eli Lilly	2008	3
Hoffmann-La Roche	2008	3
Jazz Pharma	2008	1
Bristol Myers-Squibb	2008	1
Comprehensive Neuroscience	2008	1
Depression & Anxiety (journal)	2008	10 (Deputy Editor)